Marinus Pharmaceuticals’ (MRNS) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report released on Friday morning, Benzinga reports.

A number of other equities research analysts have also recently weighed in on MRNS. Cantor Fitzgerald dropped their price target on Marinus Pharmaceuticals from $13.00 to $4.00 and set an “overweight” rating on the stock in a research note on Friday. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Royal Bank of Canada dropped their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a report on Monday, September 23rd. Finally, StockNews.com raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, October 4th. Eight research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Marinus Pharmaceuticals has an average rating of “Hold” and an average price target of $6.07.

Marinus Pharmaceuticals Stock Up 36.9 %

Shares of Marinus Pharmaceuticals stock opened at $0.41 on Friday. Marinus Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $11.26. The stock has a market cap of $22.31 million, a P/E ratio of -0.15 and a beta of 1.14. The business’s 50 day moving average is $1.54 and its 200-day moving average is $1.61.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The business had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. During the same quarter last year, the company posted ($0.61) EPS. On average, sell-side analysts expect that Marinus Pharmaceuticals will post -1.93 EPS for the current year.

Institutional Trading of Marinus Pharmaceuticals

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth $727,000. Wellington Management Group LLP grew its holdings in shares of Marinus Pharmaceuticals by 54.8% during the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock worth $2,623,000 after purchasing an additional 85,455 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after purchasing an additional 132,689 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth $813,000. Finally, Hussman Strategic Advisors Inc. grew its holdings in shares of Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares in the last quarter. 98.80% of the stock is owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.